Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 17;75(Suppl 3):S373-S378.
doi: 10.1093/cid/ciac520.

Systematic Review of In Vitro Antimicrobial Susceptibility Testing for Bacillus anthracis, 1947-2019

Affiliations

Systematic Review of In Vitro Antimicrobial Susceptibility Testing for Bacillus anthracis, 1947-2019

Tucker Maxson et al. Clin Infect Dis. .

Abstract

Bacillus anthracis, the causative agent of anthrax, is a high-consequence bacterial pathogen that occurs naturally in many parts of the world and is considered an agent of biowarfare or bioterrorism. Understanding antimicrobial susceptibility profiles of B. anthracis isolates is foundational to treating naturally occurring outbreaks and to public health preparedness in the event of an intentional release. In this systematic review, we searched the peer-reviewed literature for all publications detailing antimicrobial susceptibility testing of B. anthracis. Within the set of discovered articles, we collated a subset of publications detailing susceptibility testing that followed standardized protocols for Food and Drug Administration-approved, commercially available antimicrobials. We analyzed the findings from the discovered articles, including the reported minimal inhibitory concentrations. Across the literature, most B. anthracis isolates were reported as susceptible to current first-line antimicrobials recommended for postexposure prophylaxis and treatment. The data presented for potential alternative antimicrobials will be of use if significant resistance to first-line antimicrobials arises, the strain is bioengineered, or first-line antimicrobials are not tolerated or available.

Keywords: Bacillus anthracis; antimicrobial resistance; bioterrorism; preparedness; susceptibility testing.

PubMed Disclaimer

References

    1. Turnbull PCB, Shadomy SV. Anthrax from 5000 BC to AD 2010. In: Bergman NH, ed. Bacillus anthracis and anthrax. Hoboken, NJ: Wiley-Blackwell, 2010: 1–15.
    1. Soule MH. Identity of bacillus subtilis, Cohn 1872. J Infect Dis 1932; 51:191–215.
    1. Swartz MN. Recognition and management of anthrax–an update. N Engl J Med 2001; 345(22):1621–6. - PubMed
    1. Shadomy SV, Smith TL. Zoonosis update. Anthrax. J Am Vet Med Assoc 2008; 233:63–72. - PubMed
    1. Brook I. The prophylaxis and treatment of anthrax. Int J Antimicrob Agents 2002; 20:320–5. - PubMed

Publication types

Substances

Grants and funding